Evidence map›Paper›PMID 23608879›Full record

Trial reportJAMA pediatrics2013

Cardiac status of children infected with human immunodeficiency virus who are receiving long-term combination antiretroviral therapy: results from the Adolescent Master Protocol of the Multicenter Pediatric HIV/AIDS Cohort Study.

Steven E Lipshultz, Paige L Williams, James D Wilkinson, Erin C Leister, Russell B Van Dyke, William T Shearer, Kenneth C Rich, Rohan Hazra, Jonathan R Kaltman, Denise L Jacobson and 5 more

Registry-linked trialAbstract readClinical TrialMulticenter Study
In one paragraph

Trial report in JAMA pediatrics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01418014 (Adolescent Master Protocol), which is not on this map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01418014 completednot on this map

Adolescent Master Protocol

TypeobservationalSponsorHarvard School of Public Health (HSPH)Ran2007 to 2021Enrolled678ConditionsHIV/AIDS
3 · Its place in the literature

Who cites it

43 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Optimal Timing of Antiretroviral Therapy Initiation in Children and Adolescents With Human Immunodeficiency Virus-Associated Pulmonary Tuberculosis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023
    Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Steven E LipshultzDepartment of Pediatrics, Universityof Miami Leonard M. Miller School of Medicine, FL, USA.
Paige L Williams
James D Wilkinson
Erin C Leister
Russell B Van Dyke
William T Shearer
Kenneth C Rich
Rohan Hazra
Jonathan R Kaltman
Denise L Jacobson
Laurie B Dooley
Gwendolyn B Scott
Nicole Rabideau
Steven D Colan
Pediatric HIV/AIDS Cohort Study (PHACS)

Funding

PHACS - Data and Operations CenterU01HD052102 · NICHD · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI WILLIAMS, PAIGE L · 2005 to 2019
$242.7M
Colorado Clinical and Translational Sciences InstituteUL1TR001082 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2013 to 2017
$48.0M
Virology CoreP30AI036211 · NIAID · BAYLOR COLLEGE OF MEDICINE · PI BUTEL, JANET S · 1994 to 2015
$21.7M
Pediatric HIV/AIDS Cohort Study (PHACS): Understanding Maternal HIV Disease through Pregnancy and the Postpartum Period and its Role in Child Health OutcomesU01HD052104 · NICHD · TULANE UNIVERSITY OF LOUISIANA · PI VAN DYKE, RUSSELL B. · 2005 to 2019
$15.7M
NCATS NIH HHS UL1 TR001082NIAID NIH HHS P30 AI036211NICHD NIH HHS 3 U01 HD052102-05S1NICHD NIH HHS 3 U01 HD052102-06S3NICHD NIH HHS 3U01HD052104-06S1NICHD NIH HHS HD052102NICHD NIH HHS HD052104NICHD NIH HHS U01 HD052102NICHD NIH HHS U01 HD052104
6 · The paper itself

Abstract

importancePrior to contemporary antiretroviral therapies (ARTs), children infected with human immunodeficiency virus (HIV) were more likely to have heart failure. This study suggests that highly active ART (HAART) does not appear to impair heart function.

objectiveTo determine the cardiac effects of prolonged exposure to HAART on HIV-infected children.

designIn the National Institutes of Health-funded Pediatric HIV/AIDS Cohort Study's Adolescent Master Protocol (AMP), we used linear regression models to compare echocardiographic measures.

settingA total of 14 US pediatric HIV clinics.

participantsPerinatally HIV-infected children receiving HAART (n = 325), HIV-exposed but uninfected children (n = 189), and HIV-infected (mostly HAART-unexposed) historical pediatric controls from the National Institutes of Health-funded Pulmonary and Cardiovascular Complications of Vertically Transmitted HIV Infection (P2C2-HIV) Study (n = 70). EXPOSURE Long-term HAART. MAIN OUTCOMES AND MEASURES: Echocardiographic measures of left ventricular (LV) function and structure.

resultsThe 325 AMP HIV-infected children had lower viral loads, higher CD4 counts, and longer durations of ART than did the 70 HIV-infected children from the P2C2-HIV Study (all P < .001). The z scores for LV fractional shortening (a measure of cardiac function) were significantly lower among HIV-infected children from the P2C2-HIV Study than among the AMP HIV-infected group or the 189 AMP HIV-exposed but uninfected controls (P < .05). For HIV-infected children, a lower nadir CD4 percentage and a higher current viral load were associated with significantly lower cardiac function (LV contractility and LV fractional shortening z scores; all P = .001) and an increased LV end-systolic dimension z score (all P < .03). In an interaction analysis by HIV-infected cohort, the HIV-infected children from the P2C2-HIV Study with a longer ART exposure or a lower nadir CD4 percentage had lower mean LV fractional shortening z scores, whereas the mean z scores were relatively constant among AMP HIV-infected children (P < .05 for all interactions). CONCLUSIONS AND RELEVANCE: Long-term HAART appears to be cardioprotective for HIV-infected children and adolescents.

Indexed as

Antiretroviral Therapy, Highly ActiveAdolescentChildCohort StudiesCross-Sectional StudiesFemaleHIV InfectionsHumansInfectious Disease Transmission, VerticalLinear ModelsMaleProspective StudiesSeverity of Illness IndexTreatment OutcomeUltrasonographyVentricular Dysfunction, Left

Identifiers

PMID23608879
PMCPMC4180681

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.